Approval was given to GSK, making its product the first antisense oligonucleotide established for the treatment of chronic hepatitis B.
News|Articles|June 7, 2004
Cosmetic firms getting nailed for chemical in varnish
Nail polish makers Estee lauder and Procter & Gamble reformulate nail polishes--take DBP pthalate out amid health concerns
Advertisement
Advertisement
Related to this article
With safety and efficacy profiles aligning with its brand-name formulation, this new patch could be key for women struggling with hormone therapy adherence.
Therapy is aimed at decreasing pathogenic IgA production and immune complex formation as well as managing the effects of existing nephron loss.
This new, nonprescription therapy expands eye relief options for patients in need of apraclonidine eye drop formulations.
The oral tablet formulation was approved for adults with weakened immune systems who have not responded to other therapy.
Teva Pharmaceuticals’ new olanzapine option is the first once-monthly subcutaneous injectable on the market for schizophrenia.
Advertisement
Advertisement
Trending on Drug Topics
1
PBM Underpayment Persists as Cost-Plus Brings New Strain | NCPA 2026
2
Q&A: Why Enforcement Is the Weak Link in State PBM Reform | NCPA 2026
3
Pharmacist Roles, Risks in Guiding AI-Enabled Medical Device Use
4
Vaccine Fatigue May Stall Patient Uptake More Than Hesitancy
5